Bariatric surgery outperforms medical management in halting obesity-related NAFLD progression. Doctors compare these approaches rigorously. Recent studies show clear advantages for surgery.
First, patients achieve substantial weight loss after bariatric procedures. They lose 25-35% of body weight within 1-2 years. In contrast, medical therapy with lifestyle changes and drugs yields modest results. Consequently, surgery reduces liver fat dramatically.
Moreover, histological improvements occur more frequently with surgery. Steatosis resolves in 66-88% of cases. Inflammation improves in 50-59%. Fibrosis regresses or resolves in 30-40%. Medical management rarely achieves such profound changes.
In addition, the BRAVES trial demonstrated superiority. Bariatric surgery resolved NASH in many patients. Lifestyle plus best medical care lagged far behind. Thus, surgery prevents progression to advanced stages.
Furthermore, long-term data confirm benefits. Surgery lowers cirrhosis risk significantly. It reduces major liver outcomes. All-cause mortality drops too. Medical approaches slow but do not reverse progression as effectively.
Patients with severe obesity benefit most. Guidelines now recommend surgery for BMI over 35 with NAFLD. Even lower BMI cases qualify if metabolic issues persist.
However, surgery carries risks. Complications include nutritional deficiencies or surgical issues. Medical therapy remains safer initially. Doctors weigh these factors carefully.
Experts emphasize sustained weight loss as the key driver. Surgery provides durability. Medications like GLP-1 agonists help but often fall short long-term.
Overall, evidence favors bariatric surgery strongly. It transforms NAFLD outcomes in obese individuals. Future research refines patient selection further.
This article was generated with the assistance of AI and edited for accuracy.